- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04007341
Effect of Dexmedetomidine on the Inflammatory Response After One-lung Ventilation
July 2, 2019 updated by: Wonjung Hwang, Seoul St. Mary's Hospital
Effect of Dexmedetomidine on the Inflammatory Response in Patients Undergoing Lung Resection Surgery
The postoperative inflammatory response is significant in lung resection surgery because of major operation and one-lung ventilation.
Dexmedetomidine has been shown to reduce pro-inflammatory cytokine levels and improve clinical outcomes.
The aim of this study was to determine the effects of dexmedetomidine on inflammatory responses after lung resection surgery.
Study Overview
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Seoul St.Mary's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- elective video-assisted thoracoscopic surgery (VATS) lobectomy
- 20 < age < 75
- American Society of Anesthesiologists (ASA) classification I~II
Exclusion Criteria:
- preoperative inflammation (CRP>10ng/#, WBC>10,000/mm3, body temperature >38#)
- steroid administration within 1 month
- hematologic / autoimmune disease
- congestive heart failure (NYHA class III~IV) or significant arrhythmia
- severe obstructive / restrictive pulmonary disease
- previous history of thoracic surgery
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Saline group
Patients in the saline group were infused with an identical volume of normal saline.
|
|
|
Experimental: Dexmedetomidine group
Patients in the dexmedetomidine group were infused with a loading dose of dexmedetomidine (1.0 mcg/kg over 10 min) and were thereafter infused at a rate of 0.5 mg/kg/h.
|
The study drug for each group was administered from the time immediately after induction of anesthesia until the end of the surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Interleukin (IL)-6
Time Frame: 24 hours after surgery
|
Blood samples were collected from the antecubital vein
|
24 hours after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 29, 2018
Primary Completion (Actual)
January 18, 2019
Study Completion (Actual)
January 18, 2019
Study Registration Dates
First Submitted
July 1, 2019
First Submitted That Met QC Criteria
July 1, 2019
First Posted (Actual)
July 5, 2019
Study Record Updates
Last Update Posted (Actual)
July 5, 2019
Last Update Submitted That Met QC Criteria
July 2, 2019
Last Verified
June 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Hypnotics and Sedatives
- Dexmedetomidine
Other Study ID Numbers
- KC16MISI0042
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.